

# Sylvain Garciaz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2433173/publications.pdf>

Version: 2024-02-01

38  
papers

467  
citations

933447

10  
h-index

752698

20  
g-index

40  
all docs

40  
docs citations

40  
times ranked

882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. <i>Cancer Discovery</i> , 2022, 12, 774-791.	9.4	18
2	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. <i>Bone Marrow Transplantation</i> , 2022, 57, 627-632.	2.4	4
3	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2022, 14, 2025.	3.7	17
4	Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. <i>Cancers</i> , 2021, 13, 5608.	3.7	10
5	Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF. <i>PLoS ONE</i> , 2020, 15, e0228878.	2.5	4
6	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020, 55, 1076-1084.	2.4	20
7	Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 23-23.	1.4	0
8	Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.. <i>Blood</i> , 2020, 136, 14-15.	1.4	2
9	IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group. <i>Blood</i> , 2020, 136, 39-40.	1.4	1
10	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019, 11, 141.	4.1	11
11	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. <i>Leukemia and Lymphoma</i> , 2019, 60, 2802-2805.	1.3	10
12	Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. <i>American Journal of Hematology</i> , 2018, 93, 729-735.	4.1	31
13	Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity. <i>Nucleic Acids Research</i> , 2018, 46, 3339-3350.	14.5	26
14	Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. <i>American Journal of Hematology</i> , 2018, 93, 1042-1049.	4.1	87
15	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. <i>Oncotarget</i> , 2017, 8, 85110-85119.	1.8	2
16	Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers. <i>Blood</i> , 2017, 130, 652-652.	1.4	5
17	Rituximab (ABVD) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. <i>British Journal of Haematology</i> , 2016, 175, 735-737.	2.5	11
18	Lenalidomide for the treatment of B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1103-1116.	4.1	20

#	ARTICLE	IF	CITATIONS
19	The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study. <i>Blood</i> , 2016, 128, 1825-1825.	1.4	1
20	Patients'™ Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings. <i>PLoS ONE</i> , 2016, 11, e0154969.	2.5	19
21	B-cell lymphoma. <i>Hematologie</i> , 2015, 21, 16-22.	0.0	0
22	Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites. <i>Haematologica</i> , 2015, 100, e155-e157.	3.5	17
23	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015, 100, e423-e427.	3.5	7
24	Cellular immunotherapy for hematological malignancies. <i>Hematologie</i> , 2015, 21, 237-246.	0.0	0
25	Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. <i>Journal of Cancer</i> , 2014, 5, 248-252.	2.5	9
26	Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. <i>Haematologica</i> , 2014, 99, 527-534.	3.5	73
27	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2014, 32, 187-191.	1.7	42
28	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 1849-1853.	1.3	6
29	Acute Immune Hematological Complication of Oxaliplatin. A Series of 3 Cases. <i>Tumori</i> , 2014, 100, e17-e19.	1.1	5
30	Haploidentical stem cell transplantation (Haplo-HSCT) with nonmyeloablative conditioning regimen (NMAC) and postinfusion cyclophosphamide in advanced non-Hodgkin lymphoma (NHL) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7039-7039.	1.6	0
31	Allogeneic hematopoietic stem cell transplantation in a cohort of 314 advanced lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8568-8568.	1.6	0
32	Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 3863-3863.	1.4	0
33	Prognostic factors and treatment of acute myeloid leukemias in adults (except for APL). <i>Hematologie</i> , 2013, 19, 69-77.	0.0	0
34	Lower Relapse and Better PFS Among Chemosensitive Patients Undergoing Allogeneic Transplantation By Haploidentical Compared With HLA-Identical DONOR: Results On A Cohort Of 94 Patients With Hodgkin's™ Lymphoma. <i>Blood</i> , 2013, 122, 2144-2144.	1.4	4
35	Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd. <i>Blood</i> , 2013, 122, 3221-3221.	1.4	0
36	Primary dedifferentiated liposarcoma of the dura mater: case report. <i>Acta Neurochirurgica</i> , 2012, 154, 1737-1738.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).. Blood, 2012, 120, 3096-3096.	1.4	0
38	Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults. Clinical Oncology in Adolescents and Young Adults, 0, , 115.	0.8	1